ZOE Health Study: The Intermittent Fasting Study

November 25, 2022 updated by: Zoe Global Limited

The Intermittent Fasting ZOE Health Study: Effects on Hunger, Mood, Energy and Symptom Burden in a UK Cohort

The timing of food intake (chrononutrition) is emerging as a key regulator of circadian rhythm in metabolic organs. A wealth of research has been conducted on intermittent fasting, and time restricted eating (TRE) specifically, investigating the temporal patterns of diet (eating window, time of eating, time of largest energy intake) and their impact on disease risk, with overall beneficial impact on health. Studies have been conducted in a parallel or single arm design, while cross-over and the efficacy of TRE in ameliorating appetite and symptom burden within an individual remains unclear.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Time Restricted Eating (TRE; a type of intermittent fasting) is a dietary pattern based on the 24h day. Practicing individuals restrict their eating/feeding window to a certain number of hours, e.g. 4h, while the remaining hours in the day are non-feeding (fasting) time. The eating window is the duration of time from the start of the first meal to the end of the last meal in a 24 hr period. The eating window in a general population has previously been quantified at 12h (American cohort of n=15,000). It is important to note that TRE differs from other intermittent fasting protocols by (i) not specifying a change in dietary intake, such as requiring caloric restriction, but rather specifying the temporal pattern of intake; and (ii) requiring consistent daily eating windows over several days. TRE protocols can vary in the length of the eating window, as well as the anchoring of that window to the time of day, such that early vs. middle vs. late TRE regimens exist.

While the cardiometabolic benefits TRE are well established by human trials, other outcomes of dietary compliance remain unexplored and thus bring into question the sustainability of and adherence to TRE as a long-term dietary regimen. Perception of hunger, mood and energy, and self-elected timings of TRE eating windows while following the dietary pattern are not well understood. In particular, the relative differences in these outcomes between an habitual and a TRE eating pattern within the same individual must be determined in order to truly evaluate the acceptability of TRE on a per-individual basis.

The Intermittent Fasting Study, a sub-study of the ZOE Health Study (ZHS), will test the effects of habitual eating patterns vs. a TRE protocol on hunger, mood, energy and symptom burden in an adult UK cohort using the ZHS app.

Population:

This study is open to all participants currently enrolled in the ZHS study tracking physical and mental symptom burden on a daily basis. Participants will be invited to take part in the Intermittent Fasting Study and must provide their consent in order to participate.

Design:

The study will take place remotely using a n-of-1 design, consisting of two phases with a non-randomised cross-over. Firstly, the participant will complete a baseline phase of one week, where they follow their habitual eating pattern.

Secondly, for the second and third weeks of the study, the participant will be asked to follow a TRE regimen with an eating window of ≤10 hours. The exact duration of the eating window, its timing relative to time of day, and participant dietary intake, are decisions deliberately left to the participant for two reasons; (i) to enable the participant to choose exactly the right TRE protocol that is most acceptable to them and therefore most likely to be sustainable in the long-term; (ii) to understand the trends in acceptability and feasibility of TRE regimens across this UK cohort. The participant is given the option of continuing their TRE phase beyond the minimum two weeks.

During the two phases, participants are asked to log the following outcomes in the ZHS app, on a daily basis:

  • Hunger (using visual analogue scales, VAS)
  • Mood (using VAS)
  • Energy (using VAS)
  • Symptom burden (using VAS)
  • Body weight (optional)
  • Clock time of the start of their first eating event
  • Clock time of the end of their last eating event

Participants may also be asked to log their diet during their baseline phase and their TRE phase (optional) such that the temporal effect of changing between their habitual and chosen TRE regimens on dietary intake can be determined. They will also be asked to complete questionnaires, at the start and end of the study, about their eating habits, gastrointestinal health, lifestyle and demographic.

Outcome analysis may be stratified according to demographic and other exposure parameters such as early vs. late TRE.

Study Type

Interventional

Enrollment (Anticipated)

150000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Participants on the ZOE Health Study (ZHS) app are accepted onto the study if they wish to participate and are within the UK.

The ZHS eligibility criteria are as follows:

Inclusion Criteria:

  • Adults of 18 years and above, where the app has been approved for download from the Apple App and Google Play stores.

Exclusion Criteria:

  • Unable to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Self-controlled
n-of-1 design. Participants complete a baseline habitual eating phase following by an intervention TRE phase.
Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TRE window clock time
Time Frame: 2 weeks
The chosen clock time for the TRE window (early, vs. middle, vs. late)
2 weeks
Habitual eating window clock time
Time Frame: 1 weeks
The chosen clock time for the habitual eating window
1 weeks
Hunger
Time Frame: 3 weeks (plus optional unlimited weeks)
Hunger levels reported by visual analogue scale ("how hungry did you feel yesterday?"; 0-10; where 10 is the most hungry)
3 weeks (plus optional unlimited weeks)
Mood
Time Frame: 3 weeks (plus optional unlimited weeks)
Mood levels reported by visual analogue scale ("how was your mood yesterday?"; 0-10; where 10 is most positive)
3 weeks (plus optional unlimited weeks)
Energy
Time Frame: 3 weeks (plus optional unlimited weeks)
Energy levels reported by visual analogue scale ("how energetic did you feel yesterday?"; 0-10; where 10 is most energetic)
3 weeks (plus optional unlimited weeks)
Symptom burden
Time Frame: 3 weeks (plus optional unlimited weeks)
The self-reported symptom burden while completing both habitual and TRE phases
3 weeks (plus optional unlimited weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body weight
Time Frame: 3 weeks (plus optional unlimited weeks)
Self-reported in the study app (optional)
3 weeks (plus optional unlimited weeks)
Gastrointestinal symptoms
Time Frame: 3 weeks (plus optional unlimited weeks)
Gastrointestinal symptoms self-reported by questionnaire
3 weeks (plus optional unlimited weeks)
Eating habits
Time Frame: 3 weeks (plus optional unlimited weeks)
Eating habits self-reported by questionnaire, including number of main meals and snacks per day
3 weeks (plus optional unlimited weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Tim Spector, Pr, Zoe Ltd, King's College London

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 24, 2022

Primary Completion (Anticipated)

October 24, 2023

Study Completion (Anticipated)

October 24, 2023

Study Registration Dates

First Submitted

September 23, 2022

First Submitted That Met QC Criteria

September 23, 2022

First Posted (Actual)

September 28, 2022

Study Record Updates

Last Update Posted (Actual)

November 30, 2022

Last Update Submitted That Met QC Criteria

November 25, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • ZHS-IF

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Time Restricted Feeding

Clinical Trials on Time Restricted Eating

3
Subscribe